Top line data from VISION will be presented at the ASCO Plenary session on 7 June.
Even though WARMTH determined that median survival of 11.6 months was achieved in their retrospective analysis of 319 patients treated with Lu-PSMA monotherapy, I expect VISION survival to be better:
- VISION patients were allowed to use other drugs at the same time as Lu-PSMA
- The patients in VISION need not have exhausted all standard treatment options
- The standard of patient care may have improved since WARMTH
My educated guess is that mOS in VISION will be about 14 months. Based on this figure, the LuPIN result of 19.7 months would be 40.714286% better than VISION. Whether that would be good enough to interest Novartis or vrs37 remains to be seen.
- Forums
- ASX - By Stock
- NOX
- Lu-PSMA data
Lu-PSMA data
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
-0.005(5.75%) |
Mkt cap ! $23.96M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.1¢ | $50.65K | 608.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 131400 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 7168 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 131400 | 0.082 |
2 | 170000 | 0.081 |
2 | 200000 | 0.080 |
1 | 15000 | 0.078 |
1 | 14091 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 7168 | 1 |
0.091 | 10989 | 1 |
0.093 | 37410 | 1 |
0.095 | 54200 | 2 |
0.096 | 35000 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |